Personalized medicine in warfarin therapy

Feb 25, 2010

Researchers from the Ohio State University have developed a rapid, multiplexed genotyping method to identify the single nucleotide polymorphisms (SNPs) that affect warfarin dose. The related report by Yang et al, "Rapid Genotyping of SNPs Influencing Warfarin Drug Response by SELDI-TOF Mass Spectrometry," appears in the March 2010 issue of the Journal of Molecular Diagnostics.

Warfarin is an anti-coagulant that is commonly used to prevent blood clots and embolism. However, warfarin dosing is complicated by the fact that it interacts with many commonly used medications and even chemicals in some foods. Certain genetic variations, SNPs, also affect warfarin sensitivity and metabolism.

A group led by Dr. Haifeng M. Wu of the Ohio State University has developed a new rapid method to genotype SNPs that will help clinicians to choose appropriate doses of warfarin for individual patients. Using surface-enhanced laser desorption and ionization time-of-flight (SELDI-TOF MS), which can determine the elemental composition of a sample, Yang et al could determine the genotype of three warfarin-related SNPs in under five hours with high levels of accuracy.

Yang et al suggest that "on-site application of this method in hospital laboratories will greatly help clinicians to determine appropriate doses of to treat patients with thromboembolic disorders." In future studies, Dr Wu and colleagues plan to apply the SELDI-TOF platform to genotype other medically important SNPs that influence the efficacy and safety profiles of many drug therapies and ultimately to promote personalized health care at Ohio State University .

Explore further: Haunting tales in ship-wrecked silver

More information: Yang S, Xu L, Wu HM: Rapid Genotyping of SNPs Influencing Warfarin Drug Response by SELDI-TOF Mass Spectrometry. J Mol Diagn 2010, 162-168.

add to favorites email to friend print save as pdf

Related Stories

Genetics determine optimal drug dose of common anticoagulant

Aug 21, 2007

Genetic testing can be used to help personalize the therapeutic dosage of warfarin, a commonly-used anticoagulant, according to research published in the September 1, 2007, issue of Blood, the journal of the American Societ ...

Kidney disease affects response to blood thinner

Feb 18, 2009

Patients with reduced kidney function require lower doses of the anticoagulant drug warfarin, and may need closer monitoring to avoid serious bleeding complications, suggests a study in the April 2009 issue of the Journal of ...

Right warfarin dose determined by 3 genes

Mar 20, 2009

Researchers at Uppsala University, together with colleagues at the Karolinska Institute and the Sanger Institute, have now found all the genes the determine the dosage of the blood-thinning drug warfarin. The findings are ...

Recommended for you

The origins of handedness in life

17 hours ago

Handedness is a complicated business. To simply say life is left-handed doesn't even begin to capture the blooming hierarchy of binary refinements it continues to evolve. Over the years there have been numerous ...

Have our bodies held the key to new antibiotics all along?

21 hours ago

As the threat of antibiotic resistance grows, scientists are turning to the human body and the trillion or so bacteria that have colonized us—collectively called our microbiota—for new clues to fighting microbial infections. ...

Characterizing an important reactive intermediate

Oct 01, 2014

An international group of researchers led by Dr. Warren E. Piers (University of Calgary) and Dr. Heikki M. Tuononen (University of Jyväskylä) has been able to isolate and characterize an important chemical ...

Surfaces that communicate in bio-chemical Braille

Oct 01, 2014

A Braille-like method that enables medical implants to communicate with a patient's cells could help reduce biomedical and prosthetic device failure rates, according to University of Sydney researchers.

User comments : 0